Press Releases

ROCKVILLE, Md. , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company
Posted: August 26, 2019
Total revenue of $104.7 million , a 5.2% increase over 2018 Net product sales of $102.4 million , a 5.5% increase over 2018 Operating earnings of $42.6 million , a 19.3% increase over 2018 Submission of New Drug Application for SPN-812 on track for the second half of 2019 Revising full year 2019
Posted: August 6, 2019
Total revenue of $85.5 million and net product sales of $83.1 million . Net product sales compare to $89.1 million in 2018 and were adversely impacted by approximately $10 million in channel inventory reduction in the first quarter, coupled with seasonal insurance plan dynamics Prescription growth
Posted: May 7, 2019
ROCKVILLE, Md. , April 24, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business
Posted: April 24, 2019
ROCKVILLE, Md. , April 01, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it will host and webcast an Investor Day on
Posted: April 1, 2019
Displaying 1 - 10 of 13